An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-α mediated apolipoprotein A-I, A-II and C-III

European Journal of Pharmacology

Volumn 761, Issue , 2015, Pages 362-374

  Liu, Chao ^a   Guo, Qianqian ^a   Lu, Mengchen ^a   Li, Yunman ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Apolipoproteins; Atherosclerosis; Clematichinenoside; HepG2; Lipids; Peroxisome proliferator activated receptor

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; CLEMATICHINENOSIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SAPONIN; SHORT HAIRPIN RNA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; APOA1 PROTEIN, HUMAN; APOA2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOPLASM; DYSLIPIDEMIA; ENZYME ACTIVATION; IMMUNOASSAY; IN VIVO STUDY; LIPID DIET; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DYSLIPIDEMIAS; GENETIC TRANSFECTION; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; RABBIT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; APOLIPOPROTEIN C-III; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; HEP G2 CELLS; HUMANS; HYPOLIPIDEMIC AGENTS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PPAR ALPHA; RABBITS; RNA INTERFERENCE; SAPONINS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TRIGLYCERIDES;

EID: 84938964568     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.04.015     Document Type: Article

References (36)

1. H.B. Brewer Jr., L.A. Zech, R.E. Gregg, D. Schwartz, and E.J. Schaefer NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment Ann. Intern. Med. 98 5Pt 1 1983 623 640
2. D. Bishop-Bailey, and T. Hla Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-delta 12,14-prostaglandin J2 J. Biol. Chem. 274 24 1999 17042 17048
3. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, M.D. Joyal, K.A. Hill, M.A. Pfeffer, and A.M. Skene Intensive versus moderate lipid lowering with statins after acute coronary syndromes N. Engl. J. Med. 350 15 2004 1495 1504
4. M.J. Chapman Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease Pharmacol. Ther. 111 3 2006 893 908
5. C. Duval, M. Muller, and S. Kersten PPARalpha and dyslipidemia Biochim. Biophys. Acta 1771 8 2007 961 971
6. I.H. Dias, M.C. Polidori, L. Li, D. Weber, W. Stahl, G. Nelles, G. Nelles, T. Grune, and H.R. Griffiths Plasma levels of HDL and carotenoids are lower in dementia patients with vascular comorbidities J. Alzheimer's Dis. 40 2 2014 399 408
7. J.C. Fruchart, and P. Duriez PPAR-α and atherosclerosis from basic research to clinical applications Int. Congr. Ser. 1262 2004 25 29
8. J.J. Guilbert The world health report 2002-reducing risks, promoting healthy life Educ. Health 16 2 2003 230
9. C.C. Hedrick, and A.J. Lusis Apolipoprotein A-II: a protein in search of a function Can. J. Cardiol. 10 4 1994 453 459
10. K. Huard, P. Bourgeois, D. Rhainds, L. Falstrault, J.S. Cohn, and L. Brissette Apolipoproteins C-II and C-III inhibit selective uptake of low- and high-density lipoprotein cholesteryl esters in HepG2 cells Int. J. Biochem. Cell Biol. 37 6 2005 1308 1318
11. F.Y. Jin, V.S. Kamanna, M.Y. Chuang, K. Morgan, and M.L. Kashyap Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2) Arterioscler. Thromb. Vasc. Biol. 16 8 1996 1052 1062
12. J.P. Kehrer, S.S. Biswal, E. La, P. Thuillier, K. Datta, S.M. Fischer, and J.P. Vanden Heuvel Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886 Biochem. J. 356 Pt 3 2001 899 906
13. L. Kuang, K. Zhang, and Chinese Pharmacopoeial Commission Pharmacopoeia of the People's Republic of China 2005 2005 People's Medical Publishing House
14. K.K. Koh, M.J. Quon, R.S. Rosenson, W.J. Chung, and S.H. Han Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates Int. J. Cardiol. 124 2 2008 149 159
15. C. Kilkenny, W. Browne, I.C. Cuthill, M. Emerson, and D.G. Altman Animal research: reporting in vivo experiments: the ARRIVEguidelines Br. J. Pharmacol. 160 2010 1577 1579
16. V. Khanna, M. Jain, V. Singh, J.S. Kanshana, P. Prakash, M.K. Barthwal, P.S. Murthy, and M. Dikshit Cholesterol diet withdrawal leads to an initial plaque instability and subsequent regression of accelerated iliac artery atherosclerosis in rabbits PLoS One 8 2013 10
17. L.F. Liu, X.L. Ma, Y.X. Wang, F.W. Li, Y.M. Li, Z.Q. Wan, and Q.L. Tang Triterpenoid saponins from the roots of Clematis chinensis Osbeck J. Asian Nat. Prod. Res. 11 5 2009 389 396
18. X. Li, M. Yang, H. Wang, Y. Jia, P. Yan, G. Boden, G. Yang, and L. Li Overexpression of JAZF1 protected ApoE-deficient mice from atherosclerosis by inhibiting hepatic cholesterol synthesis via CREB-dependent mechanisms Int. J. Cardiol. 177 1 2014 100 110
19. T.W. Mak The Gene Knockout Factsbook, Two-Volume Set vol. 1 1998 Academic Press
20. J. McGrath, G. Drummond, E. McLachlan, C. Kilkenny, and C. Wainwright Guidelines for reporting experiments involving animals: the ARRIVE guidelines Br. J. Pharmacol. 160 2010 1573 1576
21. M. Mansour The roles of peroxisome proliferator-activated receptors in the metabolic syndrome Prog. Mol. Biol. Transl. Sci. 121 2014 217 266
22. S.F. Maiga, A.D. Kalopissis, and M. Chabert Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes Biochimie 96 2014 56 66
23. B.P. Neve, J.C. Fruchart, and B. Staels Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis Biochem. Pharmacol. 60 8 2000 1245 1250
24. M. Nagasawa, T. Hara, A. Kashino, Y. Akasaka, T. Ide, and K. Murakami Identification of a functional peroxisome proliferator-activated receptor (PPAR) response element (PPRE) in the human apolipoprotein A-IV gene Biochem. Pharmacol. 78 5 2009 523 530
25. X. Niu, J. Xiong, L. Bai, W. Fang, and Y. Li Effect of AR on abnormal lipid metabolism and atherosclerosis in rats Chin. J. New Drugs 22 1 2013 83 88
26. P.E. Poleni, A. Bianchi, S. Etienne, M. Koufany, S. Sebillaud, P. Netter, B. Terlain, and J.Y. Jouzeau Agonists of peroxisome proliferators-activated receptors (PPAR) alpha, beta/delta or gamma reduce transforming growth factor (TGF)-beta-induced proteoglycans' production in chondrocytes Osteoarthr. Cartil. 15 5 2007 493 505
27. Pokorný J., 2008. Biochemistry of lipids, lipoproteins and membranes. ln: dennis e. vance and jean e. vance Lipids and atherosclerosis roan jornal of ld n and hnology, pp. 579-605
28. D.J. Rader, and S.M. Haffner Role of fibrates in the management of hypertriglyceridemia Am. J. Cardiol. 83 9B 1999 30F 35F
29. M. Romero-Gomez APOC3 polymorphisms and non-alcoholic fatty liver disease: resolving some doubts and raising others J. Hepatol. 55 6 2011 1184 1186
30. K. Schoonjans, B. Staels, and J. Auwerx Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression J. Lipid Res. 37 5 1996 907 925
31. A. Shah, D.J. Rader, and J.S. Millar The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans Atherosclerosis 210 1 2010 35 40
32. W. Shou, Y. Wang, F. Xie, B. Wang, L. Yang, H. Wu, Y. Wang, Z. Wang, J. Shi, and W. Huang A functional polymorphism affecting the APOA5 gene expression is causally associated with plasma triglyceride levels conferring coronary atherosclerosis risk in Han Chinese Population Biochimica Biophys. Acta 1842 11 2014 2147 2154
33. C. Vedhachalam, P.T. Duong, M. Nickel, D. Nguyen, P. Dhanasekaran, H. Saito, G.H. Rothblat, S. Lund-Katz, and M.C. Phillips Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles J. Biol. Chem. 282 34 2007 25123 25130
34. S. Yan, X. Zhang, H. Zheng, D. Hu, Y. Zhang, Q. Guan, L. Liu, Q. Ding, and Y. Li Clematichinenoside inhibits VCAM-1 and ICAM-1 expression in TNF-alpha-treated endothelial cells via NADPH oxidase-dependent IkappaB kinase/NF-kappaB pathway Free Radic. Biol. Med. 78 2015 190 201
35. O. Ziouzenkova, and J. Plutzky Exogenous and endogenous mechanisms of PPAR activation: implications for inflammation and atherosclerosis Int. Congr. Ser. 1262 2004 147 151
36. R. Zhang, W. Fang, D. Han, L. Sha, J. Wei, L. Liu, and Y. Li Clematichinenoside attenuates myocardial infarction in ischemia/reperfusion injury both in vivo and in vitro Planta Med. 79 14 2013 1289 1297